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1288Objectives: We sought to identify factors associated with the timing and surgical outcomes of the superior
cavopulmonary anastomosis.
Methods: The Pediatric Heart Network’s Infant Single Ventricle trial database identified participants who un-
derwent superior cavopulmonary anastomosis. Factors potentially associated with age at superior cavopulmo-
nary anastomosis, length of stay and death by 14 months of age were evaluated. Factors included subject
demographics, cardiac anatomy, measures from neonatal hospitalization and pre–superior cavopulmonary anas-
tomosis visit, adverse events, echocardiographic variables, intraoperative variables, superior cavopulmonary
anastomosis type, and number of concurrent cardiac surgical procedures. Age at superior cavopulmonary anas-
tomosis was analyzed using Cox proportional hazards regression. Natural log length of stay was analyzed by
multiple linear regression.
Results: Superior cavopulmonary anastomosis was performed in 193 subjects at 5.2 months of age (interquartile
range, 4.2, 6.2) and weight of 5.9 kg (interquartile range, 5.3, 6.6). The median length of stay was 7 days (in-
terquartile range, 6, 10). There were 3 deaths and 1 transplant during the superior cavopulmonary anastomosis
hospitalization, and 3 deaths and 3 transplants between discharge and 14 months of age. Age at superior cavo-
pulmonary anastomosis was associated with center and interstage adverse events. A longer length of stay was
associated with younger age and greater case complexity. Superior cavopulmonary anastomosis type, valve re-
gurgitation, ventricular ejection fraction, and ventricular end-diastolic pressure were not independently associ-
ated with age at superior cavopulmonary anastomosis or the length of stay.
Conclusions:Greater case complexity andmore frequent interstage adverse events are associated with an earlier
age at superior cavopulmonary anastomosis. Significant variation in age at superior cavopulmonary anastomosis
among centers, independent of subject factors, highlights a lack of consensus regarding the optimal timing. Fac-
tors associated with length of stay could offer insights for improving presuperior cavopulmonary anastomosis
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The Journal of Thoracic and Cardiovascular SurThe vast majority of children with single ventricle physiol-
ogy undergo superior cavopulmonary anastomosis (SCPA)
as a part of staged palliation. The factors associated with
surgical outcomes have been addressed predominantly
by single-center studies with varying and often conflicting
results. These studies have identified age, weight-for-age,
pulmonary artery pressure, ventricular morphology, atrio-
ventricular valve regurgitation, and cardiopulmonary bypass
time as variables associated with SCPA outcomes.1-7
However, the optimal timing for the procedure remains
a topic of debate and has varied by center, in part, owing to
a lack of consistent associations across these studies. This
practice variation across centers could also play a role in
determining the outcomes.8-10
With detailed clinical data from a multicenter network,
the Infant Single Ventricle trial database offered a unique
opportunity to evaluate factors associated with the timing
of SCPA and subsequent surgical outcomes in infants un-
dergoing SCPA. The present study sought to identify factors
associated with SCPA timing and surgical outcomes.gery c May 2013
Abbreviations and Acronyms
LOS ¼ length of stay
SCPA ¼ superior cavopulmonary anastomosis
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From August 2003 through July 2008, the Pediatric Heart Network con-
ducted a randomized, double-blind, placebo-controlled clinical trial com-
paring the effects of angiotensin-converting enzyme inhibitor with those
of placebo on somatic growth in infants with a single ventricle
(ClinicalTrials.gov identifier NCT00113087). Infants 45 days old or youn-
ger with single ventricle physiology, stable systemic and pulmonary blood
flow, and planned SCPAwere enrolled at 10 North American centers. They
were followed up from enrollment until 14 months of age. No significant
differences were found between the placebo and treatment groups. Detailed
descriptions of the Infant Single Ventricle trial design and methods, includ-
ing enrollment, drug allocation, follow-up, data analysis, and results have
been previously published.11,12
The trial database was queried for all infants undergoing SCPA during
the study period. Age at SCPAwas the outcome for surgical timing. Death,
heart transplantation, hospital length of stay (LOS), unanticipated surgical
or cardiac catheterization interventions after SCPA, days on ventilator, and
interval until last chest tube removal were the clinical outcomes of interest.
Unanticipated interventions included all post-SCPA cardiac catheter inter-
ventions and additional cardiac surgeries that occurred before discharge,
excluding chest closure. The number of unanticipated interventions was di-
chotomized as none or 1 or more; total days on ventilator as 2 days or less or
more than 2 days; and interval until last chest tube removal as 5 days or less
or more than 5 days after SCPA. These thresholds for total days on venti-
lator and days until last chest tube removal represented a consensus opinion
of suboptimal outcomes by the authors but also approximated the greatest
quartile of days (rounded to an even number). Thosewho died or underwent
heart transplantation during the SCPA hospitalization were excluded from
the analyses of SCPA hospital LOS, days on ventilator, and interval until
last chest tube removal. Potentially associated factors were selected from
subject demographics, cardiac anatomy, measures from the neonatal hospi-
talization and clinical assessments at the pre-SCPA visit, adverse events
during the interstage period between discharge from the neonatal hospital-
ization and SCPA, type of SCPA performed, and number of concurrent car-
diac surgical procedures at SCPA (see Appendix 2). Adverse events were
classified as nonserious, moderately serious, and serious using the Com-
mon Terminology Criteria for Adverse Events, version 3.0.13 All serious
adverse events were adjudicated by an independent physician who was un-
aware of the treatment group assignment. Ventricular mass and volume
measured by a core laboratory, and mass/volume ratio are expressed as
z scores relative to the body surface area and age, respectively.14
Angiotensin-converting enzyme inhibitor use was determined by whether
the subject was taking any form of angiotensin-converting enzyme inhibi-
tor (either an assigned study drug or open label medication) at the pre-
SCPA clinical visit. The brain natriuretic peptide level was obtained at
the pre-SCPA clinic visit and was measured at a central laboratory.
Statistical Analysis
Descriptive statistics for subject andSCPAhospitalization characteristics
are presented as the median and interquartile range for continuous measures
with a skewed distribution, mean standard deviation for other continuous
measures, and frequency and percentage for categorical variables.
Age at SCPAwas analyzed using Cox proportional hazards regression,
which allowed for the introduction of interstage adverse events as time-
varying covariates. The LOS was analyzed after natural log transformation
using multivariate linear regression. The linearity of associations with LOS
was explored using generalized additive models. Dichotomous clinicalThe Journal of Thoracic and Caroutcomes were analyzed using logistic regression with Firth’s penalized
likelihood applied when the center was included in the models. To identify
any possible nonlinear associations with the dichotomous outcome and
time-to-event outcome, tertiles, median cutoffs, and square root or natural
log transformations of potential associated factors were evaluated in logis-
tic regression and Cox proportional hazards modeling.
Variables were considered in the multivariate model selection when the
univariate or center-adjusted association was significant at P  .15. All
models were adjusted for center to account for any differences in clinical
management strategies between centers that were not fully captured by the
InfantSingleVentricledatabase. Stepwise selectionmethodswereused tode-
termine all final models; predictors with P .05 remained in the model. The
effects of mean pulmonary artery pressure (n¼ 98) and transpulmonary gra-
dient (n¼ 60) were explored in univariate and multivariate analysis but were
not included in the final modeling because of the large amount of missing
data. Missing values were not imputed. Statistical analyses were performed
using SAS Statistical Software, version 9.2 (SAS Institute, Cary, NC).RESULTS
Subject and SCPA Hospitalization Characteristics
Of the 230 subjects randomized in the trial, 193 (84%) un-
derwent SCPA; 5 randomized subjects did not undergoSCPA
but remained in the trial. The remainder withdrew from the
trial before SCPA because of death (n ¼ 18), family prefer-
ence (n¼ 8), heart transplantation (n¼ 3), physician prefer-
ence (n ¼ 1), lost to follow-up (n ¼ 1), and other (n ¼ 1).
The details of the SCPA hospitalization overall and strati-
fied by type of SCPA are listed in Table 1.With the exception
of the proportion of subjects undergoing aortopulmonary
shunt takedown, the subject characteristics did not signifi-
cantly differ by the type of SCPA performed. A trend
(P ¼ .06) was seen toward more arrhythmia in subjects un-
dergoing Hemi-Fontan procedures.Deaths and Heart Transplantations After SCPA
There were 3 deaths and 1 heart transplantation that
occurred during the SCPA hospitalization. An additional 3
deaths and 3 heart transplantations occurred between
SCPA hospital discharge and the final study visit at 14
months of age (Table 2). The incidence of death was 3%
and of heart transplantation was 2% by 14 months of age.
Deaths occurred predominantly in subjects with morpho-
logic right ventricles, although it should be noted that 72%
of the cohort had a morphologic right ventricle. Those who
died also generally had low weight-for-age z scores, with
scores ranging from4.2 to1.0. The average weight-for-
age z score among those who survived SCPA was 1.61
(95% confidence interval,1.77 to1.45).Age at SCPA
The median age at SCPA was 5.2 months (interquartile
range, 4.2, 6.2). The Cox proportional hazards regression
model (n ¼ 169, R2 ¼ 0.43) identified independent associa-
tions of younger age at SCPA with the following factors:
center, nonblack race, younger age at neonatal palliative sur-
gery, performance of the Norwood procedure, time-relateddiovascular Surgery c Volume 145, Number 5 1289
TABLE 1. Summary of the Characteristics of the SCPA Hospitalization
Characteristic
All subjects
(n ¼ 193)
Type of SCPA
P value*
BBDCPA
(n ¼ 28)
BDCPA
(n ¼ 134)
Hemi-Fontan
(n ¼ 23)
Hemi-Fontan with
BCA (n ¼ 3)
Kawashima
(n ¼ 5)
Age at SCPA (mo)
Median 5.2 5.4 5.1 5.6 5.0 6.7 .36
IQR 4.2, 6.2 4.6, 6.9 4.1, 6.0 4.1, 6.0 4.6, 7.1 5.3, 7.5
Gender .89
Male 136 (70) 20 (71) 94 (70) 16 (70) 3 (100) 3 (60)
Female 57 (30) 8 (29) 40 (30) 7 (30) 0 2 (40)
Race .34
White 153 (80) 19 (68) 110 (83) 18 (78) 3 (100) 3 (60)
Black 27 (14) 7 (25) 17 (13) 2 (9) 0 1 (20)
Other 12 (6) 2 (7) 6 (5) 3 (13) 0 1 (20)
Ventricular morphology .027
Left 34 (18) 3 (11) 26 (19) 5 (22) 0 0
Right 138 (72) 17 (61) 97 (72) 18 (78) 3 (100) 3 (60)
Mixed 21 (11) 8 (29) 11 (8) 0 0 2 (40)
Concurrent cardiac surgical procedures (n) .50
Median 1.0 2.0 1.0 1.0 1.0 1.0
IQR 1, 2 1, 2 1, 2 0, 2 1, 2 0, 1
Surgical procedures (n)y
Atrial septectomy 20 (10) 3 (11) 12 (9) 5 (22) 0 0 .43
Patch repair of pulmonary artery stenosis 71 (37) 9 (32) 47 (35) 11 (48) 1 (33) 3 (60) .55
Takedown of aortopulmonary shunt 30 (16) 10 (36) 18 (13) 1 (4) 1 (33) 0 .015
Takedown of RV-PA conduit 45 (23) 5 (18) 34 (25) 3 (13) 2 (67) 1 (20) .25
Hospital LOS (d) .12
Median 7 8.5 7.0 8.0 8.0 8
IQR 6, 10 6, 13 6, 9 7, 11 6, 12 7, 8
ICU LOS (d) .22
Median 4.0 5.0 4.0 4.0 3.0 4.0
IQR 3, 5 3, 7 3, 5 3, 5 2, 8 4, 6
Ventilator support duration (d) .79
Median 2.0 2.0 2.0 2.0 2.0 2.0
IQR 1, 2 1, 3 1, 2 1, 2 1, 2 1, 2
Interval to last chest tube removed (d) .09
Median 3.0 4.0 3.0 4.0 5.0 4.0
IQR 2, 4 2, 5 2, 4 3, 4 5, 5 1, 4
Postoperative arrhythmia requiring
intervention
20 (10) 2 (7) 11 (8) 6 (26) 1 (33) 0 .06
Bradycardia requiring artificial pacemakerz 13 (62) 2 (100) 7 (58) 4 (67) 0 0 .57
Other arrhythmiaz 4 (19) 0 3 (25) 0 1 (100) 0 .16
Interventional cardiac catheterizations
0 184 (95) 27 (96) 126 (94) 23 (100) 3 (100) 5 (100)
1 4 (2) 0 4 (3) 0 0 0
2 5 (3) 1 (4) 4 (3) 0 0 0
Postoperative surgery (minus chest closure)
0 173 (90) 24 (86) 120 (90) 21 (91) 3 (100) 5 (100)
1 16 (8) 4 (14) 10 (7) 2 (9) 0 0
2 4 (2) 0 4 (3) 0 0 0
Subjects discharged with supplemental
oxygen
30 (16) 2 (7) 26 (20) 2 (9) 0 0
Oxygen saturation at dischargex 82.1  5.0 81.7  4.7 82.0  5.2 82.5  4.5 78.7  6.1 85.8  3.7
Discharge medications .29
Median 4.0 3.5 4.0 4.0 2 4.0
IQR 3, 5 3, 5 3, 5 2, 5 2, 2 3, 4
Any adverse event 52 (27) 9 (32) 35 (26) 6 (26) 1 (33) 1 (20) .94
(Continued)
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TABLE 1. Continued
Characteristic
All subjects
(n ¼ 193)
Type of SCPA
P value*
BBDCPA
(n ¼ 28)
BDCPA
(n ¼ 134)
Hemi-Fontan
(n ¼ 23)
Hemi-Fontan with
BCA (n ¼ 3)
Kawashima
(n ¼ 5)
Adverse event typesy
Cardiac general/arrhythmia 17 (9) 2 (7) 12 (9) 1 (4) 1 (33) 1 (20) .32
Cardiac general 9 (5) 1 (4) 6 (4) 0 1 (33) 1 (20) .08
Cardiac arrhythmia 8 (4) 1 (4) 6 (4) 1 (4) 0 0 1.00
Infection 17 (9) 6 (21) 9 (7) 2 (9) 0 0 .17
Pulmonary/upper respiratory 19 (10) 2 (7) 16 (12) 1 (4) 0 0 .84
Data presented as median and IQR, n (%), mean  SD. Subjects who died or underwent heart transplantation before stage 2 hospital discharge were excluded from summary of
hospital LOS, ICU LOS, total ventilator duration, and interval until last chest tube was removed. SCPA, Superior cavopulmonary anastomosis; BBDCPA, bilateral bidirectional
cavopulmonary anastomoses; BDCPA, bidirectional cavopulmonary anastomosis; BCA, bilateral cavopulmonary anastomoses; IQR, interquartile range; RV-PA, right ventricular-
pulmonary artery; LOS, length of stay; ICU, intensive care unit. *P values assessed significance of difference between types of SCPA, using Kruskal-Wallace test for skewed
continuous data, analysis of variance for other continuous data, and Fisher’s exact test for percentages. yCategories associated with 10% of subjects summarized. zPercentage
determined by subjects with arrhythmia. xIncluded only subjects who were not discharged with supplemental oxygen.
Cnota et al Congenital Heart Disease
C
H
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events, and the presence of accessory pulmonary blood
flow at pre-SCPA cardiac catheterization (Table 3).
LOS After SCPA
The median LOS was 7 days (interquartile range, 6, 10).
After adjusting for center differences, the multivariate lin-
ear regression model of log LOS (n¼ 170, R2¼ 0.33) iden-
tified independent associations of a longer LOS with the
following factors: greater number of ventilator days during
the neonatal palliative surgery, lower weight-for-age z score
at pre-SCPA clinic visit, greater end systolic volume z score
relative to body surface area on pre-SCPA echocardiogram,
younger age at SCPA (log), and greater number of concur-
rent cardiac procedures at SCPA (Table 3).
Occurrence of 1 or More Unanticipated
Interventions During SCPA Hospitalization
At least 1 unanticipated surgical or cardiac catheterization
intervention occurred during SCPA hospitalization in 12%
of our subjects. The types and frequencies of interventions
are listed in Table 5. After adjusting for center, the multivar-
iate logistic regression model (n ¼ 172, c-statistic ¼ 0.86)
TABLE 2. Characteristics of subjects who died and subjects who underwe
Interval to
outcome (d)
ACE inhibitor use
at pre-SCPA visit
Discharged
after SCPA Gender
Age at
SCPA (mo
Death
1 No No Male 5.0
10 Yes No Female 4.9
66 No Yes Female 5.7
95 No Yes Male 5.1
144 No No Male 3.4
238 No Yes Male 8.2
Heart transplantation
70 Yes No Male 3.0
94 Yes Yes Female 5.9
103 No Yes Male 3.3
121 No Yes Male 2.4
SCPA, Superior cavopulmonary connection; ACE, angiotensin-converting enzyme; BNP, b
The Journal of Thoracic and Caridentified that the occurrence of 1 or more unanticipated
interventions was associated with a lower weight-for-
age z score and higher ventricular mass z score relative to
the body surface area on the pre-SCPA echocardiogram
(Table 4).
Mechanical Ventilation for Longer Than 2 Days after
SCPA
Mechanical ventilation was used for longer than 2 days
after SCPA in 23% of subjects. After adjusting for center,
the multivariate logistic regression model (n¼ 164, c-statis-
tic, 0.81) identified independent associations of mechanical
ventilation for longer than 2 days with the following factors:
younger than 140 days (lower tertile) of age at SCPA, brain
natriuretic peptide greater than 135 pg/mL, and a greater
number of concurrent cardiac surgical procedures at
SCPA (Table 5).
Final Chest Tube Removed More Than 5 Days After
SCPA
The final chest tube was removed more than 5 days
after SCPA in 14% of subjects. After adjusting for center,
the multivariate logistic regression model (n ¼ 174,
nt heart transplantation after SCPA
)
Weight-for-age
z score
Ventricular
type
Oxygen saturation
by pulse oximeter (%)
Pre-SCPA
BNP (pg/mL)
4.12 Right 70 801.0
1.37 Right 80 171.0
2.96 Left 67 1190.0
1.03 Right 72 141.0
2.23 Right 80
2.69 Right 59
1.73 Right 76 490.0
2.37 Right 70 135.0
Right 65
2.83 Right 71 30.5
rain natriuretic peptide.
diovascular Surgery c Volume 145, Number 5 1291
TABLE 3. Multivariate models of age at SCPA and SCPA hospital LOS
Age at SCPA (mo) (R2 ¼ 0.43) (n ¼ 169) Age at SCPA (mo) df HR (95% CI) P value
Center Reference 9 Reference <.001
Race
White 5.18 (4.2, 6.0) 2 1.93 (1.2, 3.1) .005
Black 6.03 (4.8, 7.4) Reference
Other 4.52 (3.0, 5.7) 3.03 (1.4, 6.4)
Age at stage 1 (d), log transformation 5.20 (4.2, 6.2) 1 0.55 (0.41, 0.75) <.001
Norwood procedure
Yes 5.02 (4.1, 6.0) 1 1.63 (1.1, 2.4) .014
No 5.64 (5.0, 6.5) Reference
Interstage pulmonary adverse event
Yes 4.89 (3.9, 6.0) 1 1.52 (1.1, 2.2) .023
No 5.43 (4.6, 6.3) Reference
Interstage cardiac adverse event
Yes 4.74 (3.8, 5.7) 1 2.31 (1.5, 3.5) <.001
No 5.31 (4.4, 6.3) Reference
Accessory sources of pulmonary blood flow before SCPA
Yes 4.46 (4.0, 5.1) 1 2.18 (1.2, 3.8) .006
No 5.28 (4.4, 6.3) Reference
SCPA hospital LOS (d) natural log transformations (R2 ¼ 0.33) (n ¼ 170) Predictor df Slope (95% CI) P value
Site Reference 9 Reference .10
Ventilator duration during palliative surgery (d) (square root) 2.60  1.05 1 0.13 (0.05, 0.21) .003
Weight-for-age z score before SCPA 1.61  1.15 1 0.11 (0.19,0.04) .003
Pre-SCPA end-systolic volume BSA-adjusted z score 3.37  3.79 1 0.039 (0.017, 0.060) <.001
Age at SCPA, log transformation (d) 5.07  0.30 1 0.49 (0.79,0.18) .002
Cardiac surgical procedures concurrent with SCPA (n) 1.47  1.12 1 0.16 (0.07, 0.25) <.001
HRs and slopes associated with continuous variables represent effect of 1-unit increase of continuous variable on outcome. Data presented as median (IQR), or mean SD, unless
otherwise noted. SCPA, Superior cavopulmonary anastomosis; LOS, length of stay; HR, hazard ratio; CI, confidence interval; BSA, body surface area.
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final chest tube removal at more than 5 days with a lower
pre-SCPA ventricular ejection fraction (Table 4).TABLE 4. Multivariate models of post-SCPA unintended intervention, ven
Post-SCPA unintended intervention (c-statistic ¼ 0.86) No intervention
Site Referenc
Weight-for-age z score 1.52  1
BSA-adjusted mass z score, median cutoff
<3.94 83 (95.4
3.94 68 (80.0
Total ventilator duration (c-statistic ¼ 0.81) 2 d (n ¼ 126)
Site Reference
BNP (pg/mL), upper tertile
135 91 (82.0)
>135 35 (66.0)
Age at SCPA, lower tertile (d)
>140 93 (81.6)
140 33 (66.0)
Concurrent cardiac surgical procedures (n) 1.43  1.22
Interval to chest tube removal (c-statistic ¼ 0.84) 5 d (n ¼ 148)
Site Reference
Pre-SCPA ejection fraction (%) 58.29  9.44
ORs and slopes associated with continuous variables represent effect of 1-unit increase of co
ratio; CI, confidence interval; BSA, body surface area; BNP, brain natriuretic peptide.
1292 The Journal of Thoracic and Cardiovascular SurDISCUSSION
By assessing the factors associated with age at SCPA and
measures of surgical outcome, the results of the presenttilator duration, and interval to chest tube removal
(n ¼ 151) Intervention (n ¼ 21) df OR (95% CI) P value
e Reference 9 Reference .37
.13 2.38  1.13 1 0.50 (0.30-0.83) .007
1 .013
) 4 (4.6) Reference
) 17 (20.0) 3.92 (1.34-11.51)
>2 d (n ¼ 38) df OR (95% CI) P value
Reference 9 Reference .48
1 .005
20 (18.0) Reference
18 (34.0) 3.46 (1.45-8.28)
1 .005
21 (18.4) Reference
17 (34.0) 3.59 (1.46-8.85)
1.77  0.96 1 1.92 (1.23-3.02) .005
>5 d (n ¼ 26) df OR (95% CI) P value
Reference 9 Reference .044
52.53  9.57 1 0.93 (0.89-0.98) .003
ntinuous variable on outcome. SCPA, Superior cavopulmonary anastomosis;OR, odds
gery c May 2013
TABLE 5. Types of unanticipated postoperative procedures
Category n
Cardiothoracic surgery
Thoracostomy tube 11
Chest exploration 4
Central or Blalock-Taussig shunt 3
Device implantation 2
Diaphragm plication 2
Pulmonary artery plasty 1
Shunt revision/thrombectomy 1
Extracorporeal membrane oxygenator support 1
Mediastinal debridement 1
Right pneumonectomy 1
Heart transplantation 1
Ligation of left aortopulmonary collateral 1
Coarctation repair 1
Repair bleeding chest tube, evacuate hemothorax 1
Cardiac catheterization
Angioplasty
Pulmonary artery 4
Aorta 2
Superior vena cava 2
Stent
Superior vena cava 1
Pulmonary artery 1
Coil
Artery 5
Vein 1
Unspecified 1
Noncardiac
Extremity amputation 2
Extremity debridement 2
Extremity skin graft 1
Gastrostomy tube and Nissen fundoplication 1
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timing of SCPAwhile offering insight on the factors associ-
ated with surgical outcome.Mortality and Transplantation
Similar to previous reports, deaths were relatively uncom-
mon after SCPA.5,15 Compared with neonatal palliations,
SCPA might result in less physiologic stress, is performed in
some cases without cardiopulmonary bypass, and generally
results in more favorable postoperative hemodynamics. It is
also possible that the highest risk subjects die before
undergoing SCPA.11Subject and SCPA Hospitalization Characteristics
With the exception of the proportion of subjects undergo-
ing aortopulmonary shunt takedown, no differences in sub-
ject or SCPA hospitalization characteristics were noted
across the SCPA subtypes. Although the results of subgroup
comparisons should be interpreted cautiously, given the
small number of subjects for some groups, these resultsThe Journal of Thoracic and Cardid not identify significant differences in subjects undergo-
ing bilateral SCPA16 or a Kawashima procedure.17,18
Age at SCPA
The present analysis identified subject characteristics or
events that might result in younger age at SCPA. The time-
related occurrences of interstage cardiac and pulmonary ad-
verse events were associated with earlier SCPA. Consistent
with previous reports, events such as residual arch obstruc-
tion19 or narrowing of the aortopulmonary shunt20 likely
trigger earlier SCPA to address specific causes of the adverse
event and reduce the negative effect on single ventricle phys-
iology. In contrast, the results did not confirm previously re-
ported significant associations between age at SCPA and
several factors considered potentially clinically relevant
such as type of SCPA, oxygen saturation, presence of valve
regurgitation,15 decreased ventricular ejection fraction, and
increased ventricular end-diastolic pressure. Subjects who
were younger at neonatal palliation or a Norwood operation
might undergo SCPA sooner owing to concerns of volume
overload from accessory pulmonary blood flow or the risk
of interstage death. The independent association of race
and timing of SCPA is difficult to interpret using variables
derived solely from this data set. Largely a social construct,
race is used in health research as a surrogate for many un-
measured environmental and biologic differences between
individuals. Details of these factorswere not available. How-
ever, the observation is not entirely surprising, because racial
disparities have been described in almost every area of
healthcare, including congenital heart disease.21
The timing of SCPA is a decision that balances clinical
driving forces (eg, hypoxemia), previous operative results,
and anticipated benefits of altered physiology. However,
timing can also be influenced by the logistical challenges
of busy clinical programs, such as bed space, operating
room time, and physician availability. The interpretation
of this balance is likely different among centers, as evi-
denced by the observation that younger age was indepen-
dently associated with center after adjusting for measured
subject factors. Similar center differences in surgical timing
have been reported in the single ventricle population.22
These results highlight the lack of consensus regarding the
optimal timing of the SCPA in infantswith a single ventricle.
LOS After SCPA
Several of the factors associated with LOS could be con-
sidered more generalized measures of subject well-being
before SCPA. In particular, theweight-for-age z score, which
was chosen as the primary endpoint for themain trial, reflects
broadly on overall health in infants. Growth variables
have previously been associated with single ventricle
outcomes.1,22,23 Ventricular end-systolic volume was 1 of
several echocardiographic measures included in the statisti-
cal analyses andmight represent a surrogate for heart failure.diovascular Surgery c Volume 145, Number 5 1293
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gery could represent underlying subject characteristics that
complicate cardiothoracic surgery or some degree of perio-
perative lung injury that subsequently complicates SCPA. Fi-
nally, although the reasons that a subject undergoes an earlier
SCPA are complex, younger age at SCPA was associated
with a longer hospital stay even when adjusting for these
available factors. Given the ongoing debate about optimal
timing of SCPA,3,6 this observation is notable. Although
the benefits of post-SCPA physiology can include favorable
ventricular remodeling, less severe heart failure with im-
proved growth, and avoidance of interstage death, it is possi-
ble that the potential benefits of elective SCPA at a younger
age might be offset by potential complications related to
a complex post-SCPA clinical course.
OtherClinicalOutcomesAfter SCPA—Unanticipated
Interventions, Mechanical Ventilation, Chest Tube
Duration
Analysis of unanticipated postoperative procedures pro-
vides additional insight on the nature of the complications
that occur in association with SCPA. The most common
procedure in the present study was placement of a thoracos-
tomy tube, and the remaining procedures were quite varied.
For this reason, the multivariate model should be inter-
preted conservatively and reflects the generalized risk of un-
anticipated procedures rather than the risk of any specific
event or procedure.
The binary outcomes for mechanical ventilator duration
(>2 days) and chest tube duration (>5 days) were designed
to identify predictors of outcomes considered suboptimal.
The mean total duration for both variables was similar to
that of previous reports.1,5 Younger age, along with
elevated brain natriuretic peptide and multiple concurrent
operative procedures, was predictive of a prolonged
ventilator course. Worse ventricular function was
predictive of chest tube drainage, which might be related
to elevation in pulmonary venous pressure resulting from
high ventricular filling pressures. Although direct catheter
measurement did not support this hypothesis, the data
from invasive measurements were frequently missing and
the power could have been limited.
Study Limitations
The limitations of the present study included possible
biases introduced by the original study cohort. Missing
data, particularly hemodynamics from cardiac catheteriza-
tion, limited the inclusion of some variables in multivariate
modeling. Adverse events were only collected after the sub-
ject enrolled in the trial. For subjects who were enrolled in
the trial after discharge from the neonatal hospitalization,
events that might have occurred after discharge and before
enrollment were not captured in these analyses. The socio-
economic data were insufficient to aid in interpretation of1294 The Journal of Thoracic and Cardiovascular Surrace findings in the age at SCPA model. Finally, although
this was a relatively large cohort of single ventricle subjects,
the low prevalence of suboptimal SCPA outcomes might
have result in limited power to detect associations in the
multivariate model results listed in Table 4.
CONCLUSIONS
This largemulticenter cohort of infants with single ventri-
cle identified factors associated with timing of SCPA and
surgical outcome. The incidence of death or heart transplan-
tation was 5% by 14 months of age. Younger age at SCPA
was associated with case complexity and interim morbid-
ities. In addition, significant practice variation in the age
at SCPA among centers, independent of subject factors,
highlighted the controversy regarding the optimal timing
of SCPA. Factors associated with LOS and other measures
of operative morbidity might offer insights for improving
pre-SCPA care and surgical outcome. The risks and benefits
of elective SCPA at younger age require additional study.
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APPENDIX 2. LIST OF PREDICTORS EXPLORED
The following list presents all the potential predictors
that were explored. Tertiles and median cutoffs were in-
cluded in the logistic regression analyses to understand
any possible nonlinear association. In addition, when asso-
ciations appeared nonlinear according to the tertiles, the
lowest tertile or greatest tertile might have been analyzed
as a dichotomous predictor. In the analysis of the length
of stay, the associations of predictors with the outcome
were explored using the generalized additive model regres-
sions and plots.
Treatment
NITTenalapril (angiotensin-converting enzyme inhibitor)
at pre-SCPA visit
Percentage of time taking enalapril or angiotensin-
converting enzyme inhibitor
Demographics and baseline characteristics
Birth weight (kg) (observed, tertiles, log transformed,
square root transformed,<2500 g)
Gestational age (observed,<37 vs 37 weeks)
Gender
Race parent’s highest level of education (1 df and 5 df)
Annual household income (1 df and 4 df)
Ventricular morphology (left vs right and mixed)
Systemic ventricular dysfunction at baseline
Details of neonatal palliative surgery
Age at surgery
Circulatory arrest time (observed, tertiles, above/below
median)
Length of time ventilator required (observed, tertiles,
above/below median, square root transformed)
Number of interventional catheterizations during neonatal
hospitalization after palliative surgerydiovascular Surgery c Volume 145, Number 5 1295
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H
DNumber of other surgeries after palliative surgery
(collapsed to ‘‘any other surgeries’’)
Pre-SCPA measures
Pre-SCPAweight-for-age z score (observed,<2 vs2,
<1 vs 1, tertiles)
Pre-SCPA oxygen saturation (observed, tertiles, above/
below median)
Pre-SCPA brain natriuretic peptide (observed, tertiles,
low brain natriuretic peptide, log transformed)
Pre-SCPA catheterization
Mean systemic venous atrial pressure (observed, tertiles,
above/below median)
Pulmonary capillary wedge pressure (observed, tertiles,
above/below median)
End-diastolic pressure (observed, tertiles, above/below
median)
Mean pulmonary artery pressure (observed, tertiles,
above/below median)
Transpulmonary gradient (observed, tertiles, above/
below median)
Number of interventional procedures during the
catheterization
Pre-SCPA echocardiogram
Overall atrioventricular valve regurgitation
Ejection fraction (observed,>55% vs 55%, z score)
Mass/volume ratio (observed, tertiles, above/below
median)
Mass/volume ratio z score (observed, tertiles, above/
below median)1296 The Journal of Thoracic and Cardiovascular SurMass (observed, tertiles, above/below median)
Mass z score (observed, tertiles, above/below median)
End-diastolic volume (observed, tertiles, above/below
median)
End-diastolic volume z score (observed, tertiles, above/
below median)
End systolic volume (observed, tertiles, above/below
median)
End-systolic volume z score (observed, tertiles, above/
below median)
Pre-SCPA feeding
Whether the subject was consuming solid food before
SCPA (yes/no)
Total daily calories consumed (observed, tertiles, above/
below median, log transformed)
Total calories consumed per day per kilogram (observed,
tertiles, above/below median, log transformed)
Pre-SCPA feeding type
Tube fed before SCPA (yes/no)
Interstage adverse events
First serious adverse event
First cardiac general or cardiac arrhythmia adverse event
First pulmonary adverse event
Details of SCPA
Age at SCPA (observed, tertiles,<140 days vs 140
days) for SCPA outcomes
Type of SCPA (bidirectional Glenn, hemi-Fontan,
bilateral bidirectional Glenn, Kawashima)
Number of cardiac procedures concurrent with SCPAgery c May 2013
